News

1 to 9 of 14 results

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

31-03-2014

Multinational drugmakers might be crying themselves hoarse that India does not protect innovation - that…

Asia-PacificBristol-Myers SquibbFinancialGlaxoSmithKlineIndiaMerck & CoMergers & AcquisitionsMylan LaboratoriesPatentsPharmaceuticalSanofi

US FTC calls for divestments for Mylan acquisition of Agila Specialties to proceed

US FTC calls for divestments for Mylan acquisition of Agila Specialties to proceed

27-09-2013

The USA’s Federal Trade Commission will require Mylan and Agila Specialties to divest 11 generic injectable…

Agila SpecialitesGenericsMergers & AcquisitionsMylan LaboratoriesNorth AmericaStrides Arcolab

Mylan's deal to acquire Strides Arcolab's unit looks set to proceed

22-08-2013

US generics and specialty drugmaker Mylan (NYSE: MYL) $1.6-billion foreign direct investment proposal…

Agila SpecialitesAsia-PacificGenericsMergers & AcquisitionsMylan LaboratoriesRegulationStrides Arcolab

Generics briefs: Actavis/Warner Chilcott M&A delay; Canasa patent challenge

11-07-2013

US generics major Actavis (NYSE: ACT) and Ireland-based Warner Chilcott (Nasdaq: WCRX) have each received…

ActavisAptalis PharmaCanasaGenericsLegalMergers & AcquisitionsMylan LaboratoriesNorth AmericaPatentsWarner Chilcott

Mylan stumbles in $1.6 billion bid to take over injectables specialist Agila Specialties in India

09-07-2013

US generics and specialty drugs company Mylan (NYSE: MYL) faces a setback in its plan to acquire Indian…

Agila SpecialitesGenericsMergers & AcquisitionsMylan LaboratoriesStrides Arcolab

Mylan buys Indian production unit from SMS Pharma for $33 million

18-10-2012

Following speculation that started last month, India's SMS Pharmaceuticals this week confirmed that it…

Asia-PacificGenericsMergers & AcquisitionsMylan LaboratoriesProductionSMS Pharmaceuticals

Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx

01-05-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's largest generics companies, said…

Antibiotics and Infectious diseasesDoryxGenericsLegalMergers & AcquisitionsMylan LaboratoriesNeurologicalNorth AmericaNuvigilPatentsPharmaceuticalTeva Pharmaceutical IndustriesWarner Chilcott

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top